Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoine Angelergues

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Nature Reviews. Urology|June 25, 2014
Prostate cancer: cabazitaxel--the taxane of choice in the new mCRPC landscape?Stéphane Oudard, Antoine Angelergues
General and Comparative Endocrinology|April 19, 2015
Human and murine prostate basal/stem cells are not direct targets of prolactinLucila Sackmann-Sala, Antoine Angelergues, Florence Boutillon, et al.
Bulletin Du Cancer|January 7, 2017
Stéphane Oudard, Constance Thibault, Antoine Angelergues, et al.
American Journal of Clinical Oncology|June 19, 2012
Prospective and comparative evaluation of the toxicity of adjuvant concurrent chemoradiotherapy after neoadjuvant chemotherapy for breast cancerVirginie Marchand, Antoine Angelergues, Vanessa Gobaux, et al.
BJU International|April 4, 2017
Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancerAlice Clément-Zhao, Marie Auvray, Hail Aboudagga, et al.
Bulletin Du Cancer|August 12, 2023
Jérôme Alexandre, Marie-Aude Le Frère-Belda, Antoine Angelergues, et al.
Bulletin Du Cancer|January 30, 2026
[Recommendations for clinical practice Nice-Saint Paul de Vence 2024-2025: Management of advanced/relapsing endometrial cancer]Lauriane Eberst, Corinne Jeanne, Guillaume Bataillon, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2014
Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancerAntoine Angelergues, Denis Maillet, Aude Fléchon, et al.
Bulletin Du Cancer|September 15, 2022
[Practical management of PARP inhibitors: A French DELPHI consensus]Frédéric Selle, Jean-Jacques Boffa, Gabriel Etienne, et al.
Future Oncology (London, England)|August 19, 2024
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancerRayan Kabirian, Olivier Tredan, Frederik Marmé, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Nature Reviews. Urology|June 25, 2014
Prostate cancer: cabazitaxel--the taxane of choice in the new mCRPC landscape?Stéphane Oudard, Antoine Angelergues
General and Comparative Endocrinology|April 19, 2015
Human and murine prostate basal/stem cells are not direct targets of prolactinLucila Sackmann-Sala, Antoine Angelergues, Florence Boutillon, et al.
Bulletin Du Cancer|January 7, 2017
Stéphane Oudard, Constance Thibault, Antoine Angelergues, et al.
American Journal of Clinical Oncology|June 19, 2012
Prospective and comparative evaluation of the toxicity of adjuvant concurrent chemoradiotherapy after neoadjuvant chemotherapy for breast cancerVirginie Marchand, Antoine Angelergues, Vanessa Gobaux, et al.
BJU International|April 4, 2017
Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancerAlice Clément-Zhao, Marie Auvray, Hail Aboudagga, et al.
Bulletin Du Cancer|August 12, 2023
Jérôme Alexandre, Marie-Aude Le Frère-Belda, Antoine Angelergues, et al.
Bulletin Du Cancer|January 30, 2026
[Recommendations for clinical practice Nice-Saint Paul de Vence 2024-2025: Management of advanced/relapsing endometrial cancer]Lauriane Eberst, Corinne Jeanne, Guillaume Bataillon, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2014
Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancerAntoine Angelergues, Denis Maillet, Aude Fléchon, et al.
Bulletin Du Cancer|September 15, 2022
[Practical management of PARP inhibitors: A French DELPHI consensus]Frédéric Selle, Jean-Jacques Boffa, Gabriel Etienne, et al.
Future Oncology (London, England)|August 19, 2024
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancerRayan Kabirian, Olivier Tredan, Frederik Marmé, et al.
Pageof 2